Trade Pulmonx Corporation - LUNG CFD

Trading Conditions

• Spread: 0.07
• Long position overnight feeLong position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position-0.026179 %(-$1.05)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investment$1,000.00Overnight feeCharges from full value of position0.003957 %($0.16)Trade size with leverage ~ $5,000.00Short position overnight fee ~ $4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-$1.05)

• Margin. Your investment: $1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  ($0.16)

Key Stats

• Prev. Close: 7.58
• Open: 7.73
• 1-Year Change: -33.93%
• Day's Range: 7.73 - 7.91

Pulmonx Corporation Company profile

About Pulmonx Corp

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Pulmonx Corp revenues increased 48% to $48.4M. Net loss increased 51% to $48.7M. Revenues reflect United States segment increase of 54% to $25M, Europe, Middle-East and Africa ("EMEA") segment increase of 44% to $19.9M. Higher net loss reflects Selling, general and administrative increase of 41% to $61.2M (expense), Stock-based Compensation in SGA increase from $2.8M to $8.7M (expense).